China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...
Eli Lilly And Company (NYSE:LLY) announced that Chinese regulators have approved its diabetes drug tirzepatide. This approval ...
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, ...
Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart drug Trulicity when it came to glycemic control in patients with Type 2 ...
As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly's branding to promote its products. In April, U.S. District Judge ruled that Eli Lilly cannot rely ...
If half of the adults with obesity in America took Wegovy and the other new weight loss drugs, such as Eli Lilly's Zepbound, it could cost $411 billion per year, more than the $406 billion ...
Eli Lilly drug tirzepatide, marketed as Zepbound for weight management, has results from two Phase 3 studies showing reductions in the breathing problems caused by obstructive sleep apnea.
May 10 (Reuters) - About one in eight adults have taken a drug belonging to the GLP-1 class of medications for weight loss and related conditions, a poll by Kaiser Family Foundation (KFF) showed ...
, opens new tab to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. 'Absolutely and always open...we value our partnership with Lilly tremendously and I ...
Pharma major Cipla has reported a consolidated net profit of Rs 939 crore for the January to March period, up 79 percent year-on-year (YoY), compared with Rs 525.6 crore in the year-ago period.